Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | PHGDH | O43175 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352455 | 0.84 | CNR2 (0.32) | CNR2CNR1MMP1MMP2MMP9 | |
| SCHEMBL351648 | 0.77 | CNR2 (0.46) | CNR2CNR1MMP1MMP2MMP9 | |
| SCHEMBL775376 | 0.72 | CNR2 (0.58) | CNR2CNR1ALDH1A1MAPK14 | |
| SCHEMBL350900 | 0.68 | PTGS2 (0.36) | CNR2CNR1MAPTALDH1A1PTGS2 | |
| SCHEMBL12289440 | 0.66 | F2 (0.46) | CNR2CNR1MMP1MMP2MMP9 | |
| SCHEMBL352888 | 0.66 | MAOA (0.36) | CNR2CNR1MAPTALDH1A1MAPK14 | |
| SCHEMBL766938 | 0.65 | CNR2 (0.79) | CNR2CNR1MAPTKMT2AALDH1A1 | |
| SCHEMBL352174 | 0.65 | CNR2 (0.39) | CNR2CNR1MMP1MMP2MMP9 | |
| SCHEMBL10146272 | 0.65 | CNR2 (0.53) | CNR2CNR1MAPK14 | |
| SCHEMBL350411 | 0.65 | CNR2 (0.53) | CNR2CNR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885MMP1 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.